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a  b  s  t r a  c  t
Nanocrystalline  calcium phosphate  apatites  constitute the  mineral part  of hard tissues,  and  the synthesis
of  biomimetic  analogs  is now well-mastered  at  the lab-scale.  Recent  advances  in the fine  physico-
chemical  characterization of these phases enable  one  to envision  original  applications  in the medical
field  along with  a better  understanding  of the  underlying  chemistry and related  pharmacological  fea-
tures.  In  this contribution,  we specifically  focused on applications  of biomimetic  apatites in the  field  of
cancer  diagnosis or  treatment.  We first  report on the  production  and first  biological evaluations (cyto-
toxicity,  pro-inflammatory  potential,  internalization  by ZR-75-1  breast cancer  cells) of  individualized
luminescent  nanoparticles  based  on  Eu-doped apatites,  eventually  associated with  folic  acid, for medical
imaging  purposes.  We  then detail, in a first approach,  the  preparation  of tridimensional  constructs  asso-
ciating nanocrystalline  apatite  aqueous  gels  and drug-loaded  pectin  microspheres. Sustained  releases  of
a  fluorescein  analog  (erythrosin) used as  model molecule  were  obtained  over 7  days,  in comparison with
the  ceramic  or  microsphere  reference  compounds.  Such  systems  could  constitute original  bone-filling
materials  for  in  situ  delivery of  anticancer drugs.
1. Introduction
The setup and development of fine-tuned diagnosis devices and
biomimetic drug delivery systems appear today as major challenges
in modern medicine, and specifically in oncology.
Nanocrystalline calcium phosphate apatites, responding to
the general chemical formula Ca10−x(PO4)6−x(HPO4)x(OH)2−x
(0 ≤ x ≤ 2), can be seen as promising candidates for the prepa-
ration of nano-biotechnological devices (Rey et al., 2007; Roveri
et al., 2008). Indeed, they fully mimic the composition and struc-
tural features of bone mineral, which confers them a biocompatible
character. Also, they do not originate from biological sources
thus eliminating immunological or ethical issues (as well as a
poor reproducibility in compound characteristics). Their physico-
chemical characteristics and surface state have been investigated
in details, as well as their potentialities in bone regeneration appli-
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cations (see for example Rey et al., 2007, 2009; LeGeros, 2008;
Autefage et al., 2009). In contrast to well-crystallized micron-sized
hydroxyapatite, nanocrystalline apatitic systems exhibit a high
surface reactivity and their preparation is now mastered at the
lab-scale (Drouet et al., 2009). Also, recent results have shown the
possibility to retain the advantageous physico-chemical features
of apatite nanocrystals by using soft processing routes (e.g. Grossin
et al., 2010).
In this view, two domains of interest for apatite-based systems
can be more specifically considered: the preparation of individual-
ized nanoparticulate systems and the elaboration of tridimensional
biomimetic constructs.
The development of nanoparticle-based systems in medicine
has been widely described. Examples of individualized nano-
particulate systems currently investigated include metal or metal
oxide nanoparticles (e.g. gold, magnetite, gadolinium oxide),
semiconductors (e.g. quantum dots), polymeric nanoparticles or
nanocapsules, liposomes, etc. (Bruchez et al., 1998; Parak et al.,
2003; Ow et al., 2005; Fizet et al., 2009). These nano-systems
may be used as circulating entities in body fluids, associated with
limited recognition by the reticulo-endothelial system (Moghimi
et al., 2001; Moghimi and Bonnemain, 1999; Couvreur et al., 2006),
in view of specific cell addressing and internalization (Schroeder
et al., 2007), possibly with the help of a cell-targeting agent such
as folic acid (FA). The use of apatites for cellular drug delivery
(e.g. for nonviral transfection applications) or medical imaging
has also lately raised interest in the scientific community due to
the possibility to functionalize the surface of biomimetic apatite
nanocrystals with varying molecules of interest (Mondejar et al.,
2007; Bouladjine et al., 2009; Saha et al., 2009; Al-Kattan et al.,
2010). Very recently, we showed the possibility to prepare colloidal
apatite-based suspensions from ionic salts for the elaboration of
luminescent nanoparticles (Al-Kattan et al., 2010), opening new
perspectives in medical diagnosis.
The association of apatitic tridimensional constructs with
biologically relevant ions or drugs, including anticancer agents,
has also been pointed out (Lebugle et al., 2002; Barroug et al.,
2004; Josse et al., 2005; Gautier et al., 2010; Autefage et al., 2009;
Roveri et al., 2008; Drouet et al., 2008). The possibility to control
the nanocrystalline character of such systems makes it possible to
take advantage of the surface properties and enhanced bioactivity
(Cazalbou et al., 2005; Rey et al., 2007; Tran et al., 2009). Also, new
processing routes avoiding high-temperature sintering steps open
new perspectives in elaborating drug-loaded scaffolds, as low-
temperature processes are needed to retain the active structure of
numerous drugs. In the absence of specific apatite–drug interac-
tion, the simple incorporation of the drug within the apatitic matrix
often leads to uncontrolled burst release. In this context, including
drug-loaded polymer microparticles into ceramics could be a way
to improve drug release properties. Polymer microparticles incor-
porated into calcium phosphate cements (whose final composition
is apatitic) have already been described and showed interesting
delayed release properties (Ruhe et al., 2005; Habraken et al.,
2008; Girod-Fullana et al., 2010). However, despite a controlled
drug release, this type of formulations bears potential drawbacks
due in particular to the usual exothermic effect and/or pH change
occurring upon cement hardening (which could prove to be
problematic for some drugs) and to the modification of the cement
hardening kinetics as a function of the amount of associated
microspheres.
Taking into account the preceding statements, we investigated
in the present work the potentialities of biomimetic nanocrys-
talline apatite-based systems specifically in view of cancer-related
applications: either (i) for intracellular medical imaging (cancer
diagnosis) or (ii) in view of local drug delivery (e.g. anticancer drug)
in cancerous bone tissue.
In the first case, we focused on the above-mentioned lumines-
cent apatite colloids. We proved the possibility to functionalize the
surface of the apatite nanoparticles with folic acid, or “FA” (a poten-
tial cell-targeting agent), and we evaluated (i) their cytotoxicity
on different cell types: breast cancer cells (ZR-75-1) and adipose
stem cells from breast (AMSC) which are involved in progression of
closed tumor cells, (ii) their pro-inflammatory potential (by follow-
ing interactions with Human monocytes/macrophages), and (iii)
their capacity to be internalized by ZR-75-1 breast cancer cells.
Such biocompatible systems then show promise as biocompatible
luminescent nanoprobes.
In the second case, we present a novel approach for the prepa-
ration of polymer/apatite composites, involving the progressive
mild drying of an aqueous biomimetic apatite gel containing
drug-loaded microspheres. This study explores the feasibility of
incorporating low methoxy amidated pectin (LMAP) microspheres
into a nanocrystalline apatite ceramic, with the aim to study the
influence of pectin microspheres on the ceramic crystalline struc-
ture and to evaluate the composite drug release ability. To do so,
varying LMAP incorporation ratios, up to 18% (w/w), were tested
and erythrosin (a red fluorescent dye) was chosen as model drug
to be released.
2. Materials and methods
2.1. Samples preparation
The apatite colloids prepared in this work were obtained by
applying the experimental protocol that we reported previously
(Al-Kattan et al., 2010). A constant europium doping rate corre-
sponding to the final molar ratio Eu/(Ca + Eu) = 2% was used here.
Briefly, the nanocrystalline apatite precipitation was carried out in
deionized water, at room temperature and pH 9.5, from a  mixture
of calcium nitrate, europium nitrate and ammonium hydrogen-
phosphate, with the starting molar ratio (Ca + Eu)/P = 3, and in
the presence of a phospholipid moiety: 2-aminoethylphosphate
(denoted “AEP”) playing the role of biocompatible stabilizing agent
through electrostatic interparticle repulsive effects (Bouladjine
et al., 2009). After precipitation, the suspensions were aged at
100 ◦C for 16 h. The starting AEP/(Ca + Eu) molar ratio was fixed
to 1. The fluid colloids obtained after aging were then purified by
dialysis in water (cellulose membrane, cutoff 6000–8000 Da). The
pH of the colloids could then be adjusted to physiological value by
addition of sodium hexametaphosphate, prior to biological appli-
cations. In the case of syntheses performed in the presence of folic
acid (vitamin B9 or “FA”), the latter was added either in the reacting
medium before or after the aging step, typically at a  concentration
of 0.45 mM.
The preparation of the pectin–apatite composite samples
involved two successive steps: the preparation of erythrosin-
loaded pectin microspheres (ERY-LMAP), and the association of
LMAP microspheres with nanocrystalline apatite gel. In this work,
we used low-methoxy amidated pectins (LMAP) with degrees of
esterification and amidation of 30% and 19%, respectively, and an
average molecular weight of 228 000 Da, as supplied by CPKelco
(Denmark). LMAP microspheres were prepared as  follows: 3% (w/v)
pectin were dispersed into erythrosin B solutions in phosphate
buffer pH 8. ERY-LMAP microspheres were produced by ionotropic
gelation using an electrostatic bead generator (Inotech encapsu-
lator IE 50 R, Switzerland) equipped with a syringe pump and a
300 mm nozzle. The pectin solutions were dropped into a solu-
tion of calcium chloride at 500 mM (cross-linking solution) under
continuous agitation. The gelled microspheres, instantaneously
formed, were allowed to cure in the cross-linking solution for 24 h.
Then they were separated by filtration, washed with deionized
water, dehydrated in a graded series of ethanol, and dried for 48 h
at 37 ◦C.
The preparation of the pectin–apatite biocomposites was then
carried out in the shape of disks (final dimensions: 18 mm diame-
ter, 5 mm height). In a typical procedure, dried LMAP microspheres
were dispersed, in varying amounts (50, 100, 200 and 300 mg),
into a 100 ml solution of calcium nitrate Ca(NO3)2·4H2O at a
concentration of 160 g/l. A 50 ml ammonium hydrogenphosphate
(NH4)2HPO4 solution at 70 g/l was then prepared and adjusted
to pH 10.5 by addition of 5 ml of ammonia, and dropped into
the calcium–pectin suspension under continuous stirring. After
1 min of reaction, the obtained gel was filtered and washed with
deionized water. This pectin-loaded gel was finally introduced into
cylindrical moulds and pressed until total evacuation of air bubbles.
The lids of the mould were removed and the paste was allowed to
dry, in varying temperatures, during 4 days.
2.2. Physico-chemical characterizations
Calcium and europium contents were assessed by induced
coupled plasma atomic emission spectroscopy, ICP-AES (rela-
tive uncertainty 3%). The amount of mineral phosphate in the
samples was determined by colorimetry at  = 460 nm using the
yellow phospho-vanado-molybdenum complex (relative uncer-
tainty 0.5%). The AEP content in apatite colloids was drawn from
nitrogen microanalysis (relative uncertainty 0.4%).
The apatitic crystallographic structure in the samples was
checked, after freeze-drying, by powder X-ray diffraction (XRD)
using a CPS 120 INEL diffractometer and the Ka cobalt radiation
( = 1.79002 A˚). Fourier transform infrared (FTIR) analyses were
performed on a Nicolet 5700 spectrometer, in the wavenumber
range of 400–4000 cm−1 with a resolution of 4 cm−1.
The size and morphology of the samples were followed, depend-
ing on the size range of the samples, either by optical microscopy,
by scanning electron microscopy (SEM) using a JEOL scanning elec-
tron microscope (JSM-6400F) at 15 kV, or by transmission electron
microscopy (TEM) on a JEOL JEM-1011 set at 100 keV.
The particle size of apatite colloids (hydrodynamic diameter)
was determined by dynamic light scattering (DLS) using a Nano-
sizer ZS apparatus from Malvern Instruments ( = 630 nm). The
dispersion of the data points is estimated to 0.5%. Zeta poten-
tial measurements were also carried out using this apparatus. The
LMAP microspheres size distributions were measured using a laser
particle sizer (Mastersizer 2000; Malvern, UK) based on a laser
light-scattering technique. Each sample was measured in triplicate.
The weight average of volume distribution (D[4;3]) was used to
describe the particle size.
Microsphere swelling ratio was evaluated by weighing, and cal-
culated according to Eq. (1):
SR =
[
Wt −  W0
W0
]
×  100 (1)
where Wt is the microspheres weight at the given time point and
W0 the initial weight of the dry microspheres. Each experiment was
performed in triplicate.
The luminescence properties of the colloids were investigated
using a Horiba Jobin Yvon Fluorolog 3-11 spectrofluorometer
equipped with a 450 W xenon lamp. Excitation and emission
were measured at room temperature directly on the dialyzed
colloidal suspensions. Excitation spectra were recorded between
350 and 600 nm, monitoring the 5D0→
7F2 emission of Eu
3+ at
em =  612 nm (spectral bandwidth = 2 nm). Emission spectra were
recorded in the 500–700 nm range, with a  spectral bandwidth of
1 nm, under selected excitation in the 7F0→
5L6 transition of Eu
3+
at ex = 392.8 nm or in the 7F0→
5D2 transition at ex = 464.2 nm.
The transient characteristics of the emitting level 5D0 of Eu
3+ were
investigated with the phosphorimeter FL-1040, equipped with a
UV xenon flash tube. Emission decays were analyzed at chosen ex
and em on a time interval of 3.5 ms. The time resolution imposed
by the apparatus in the experimental conditions employed is 30 ms.
Fluorescent confocal microscopy was used to characterize LMAP
microspheres after release. An argon 488 nm laser was used for
excitation of erythrosin; the emission light between 505 and
530 nm was detected. Using a  Zeiss 510 confocal microscope, opti-
cal sections of 46.8 mm thick through the microspheres were taken.
For the LMAP–apatite composite systems, drug loading and
encapsulation efficiency were determined after complete degra-
dation of LMAP microspheres in pH 8 phosphate buffer. They were
calculated according to Eqs. (2) and (3), respectively:
Drug loading
=
[
AQ
total weight of microspheres by batch − AQ
]
× 100 (2)
Encapsulation efficiency (drug entrapment ability in %)
=
(
AQ
TQ
)
× 100 (3)
in  which AQ is the actual quantity of drug present in the matri-
ces (drug content) and TQ the theoretical quantity of drug (initial
erythrosin B loading dose during microspheres preparation).
Erythrosin B  release from microspheres, ceramics alone, and
composites under in vitro conditions was performed in SBF pH
7.25 (prepared according to Kokubo and Takadama, 2006) at 37 ◦C.
Standard methods of release experiments in pharmacopoeias are
hardly suitable for multi-particulate dosage forms due to the large
volumes of the vessels; a modified alternative method, proposed
by research groups working on multi-particulate dosage forms for
colon delivery was used (Atyabi et al., 2005). Briefly, composites
(containing ERY-LMAP microspheres at a  weight ratio of 6% and
9%, respectively) or ceramic specimens (accurate weight of approx-
imately 2.80 g) or ERY-LMAP microspheres (accurate weight of
approximately 100 mg) were placed in test tubes containing 10 ml
of SBF pH 7.25, at 37 ◦C under agitation at 100 rpm. Erythrosin B was
assayed by spectrophotometry (Perkin Elmer, USA) at 527 nm, in
triplicate, at various time intervals up to 7 days. Cumulated released
amounts (in percentage of the initial amounts) were plotted versus
time. Each in vitro release study was performed three times. All the
studies were performed under sink conditions for erythrosin B.
2.3. Biological assessments
2.3.1. Cytotoxicity evaluation for apatite-based colloidal
nanoparticles
The cytotoxicity of the colloids, relatively to two cell types:
human breast cancer cells ZR-75-1 and adipose tissue mesenchy-
mal stem cells (AMSC), was evaluated by way of MTT tests
performed by the ICELLTIS Company (Verniolle, France). In these
tests, cell viability is determined on the basis of mitochondrial
activity which leads to a quantifiable emission of light after
exposure with the MTT reactant (3-[4,5-dimethylthiazol-2yl]-2,5-
diphenyltetrazolium bromide).
In preparation of these tests, the cells were cultivated in humidi-
fied atmosphere with 5% CO2 at 37
◦C in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum and
1% antibiotics (penicillin/streptomycin). The cells were then placed
in 96-well culture plates (30 000 cells per well) and each test was
run in triplicate. After 24 h of preliminary incubation, the culture
medium was replaced by fresh DMEM (exempt of phenol red) and
the MTT tests were initiated.
Cell viability was assessed for varying contact times between
the colloidal nanoparticles and the cells ranging between 1 and 7
days. Additionally, 5 different concentrations of nanoparticles in
the culture medium were tested: 0, 0.1, 1, 2, 5 and 10 mg/ml. For
each MTT test, 50 ml of MTT reactant (5 mg/ml) were added to each
well and the cells were further incubated for 4 h at 37 ◦C for com-
pleting the reaction. Finally, the culture medium was replaced by a
solubilization solution (H2O 66%, DMF 20%, SDS 5%, Triton X100, at
pH 7) overnight and measurement of the light absorption at 570 nm
was carried out, as a measure of cell viability.
2.3.2. Evaluation of the pro-inflammatory potential of
apatite-based colloids – interaction with Human monocytes
Macrophages and their precursors, monocytes, are essential
cells of the immunological system, intended to mediate the inflam-
matory response to foreign substances such as nanoparticles. These
cells are in particular activated by inflammatory signals, conducing
to an increased capacity to release pro-inflammatory and cytotoxic
mediators such as Reactive Oxygen Intermediates, or “ROI” (Laskin
and Laskin, 2001). The measure of the amount of produced ROI was
thus used in this work to evaluate the intrinsic pro-inflammatory
potential of the apatite colloidal nanoparticles that we prepared.
For these measurements Human peripheral blood mononu-
clear cells were isolated from the blood of healthy volunteers
by a density gradient centrifugation method on Lymphoprep
(Abcys). Monocytes were isolated by adherence to plastic for 2 h
in Macrophage-Serum Free Medium (M-SFM) (Gibco Invitrogen) at
37 ◦C, 5% CO2.
The monocytes were plated in 96-well Falcon plates
(3 × 105monocytes/well). The oxygen dependent respiratory
burst of monocytes was measured by chemiluminescence as
previously described (Lefevre et al., 2010) in the presence of
5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) using ther-
mostatically (37 ◦C) controlled luminometer (Wallac 1420 Victor2).
The luminol detects both reactive oxygen and nitrogen intermedi-
ates (O2
•−, ONOO−,  OH•). The generation of chemoluminescence
was monitored continuously for 1 h after incubation of the cells
with luminol (66 mM) and after colloids challenge at various
concentrations (1.2, 12, 60 and 120 mg/ml). The measurements
was realized in triplicate. The negative control was based on
experiments carried out in the absence of nanoparticles. Statistical
analysis was performed using the area under the curve expressed
in counts × seconds.
2.3.3. Evaluation of the internalization of colloidal apatite
nanoparticles by ZR-75-1 breast cancer cells
The possible internalization of apatite colloidal nanoparticles
by cancer cells was checked on ZR-75-1 breast cancer cells, for a
concentration of nanoparticles in the culture medium of 1.5 mg/ml.
A negative control was carried out without nanoparticles.
These tests, realized in triplicate, were carried out by the
ICELLTIS Company (Verniolle, France). 24 h after seeding, the col-
loid was added to the cells during 24 h. Then, after washing with
PBS buffer, the cells were counted and centrifuged. The residual pel-
lets were dissolved in HCl 37% and incubated for 30 min in view of
quantification of the intracellular Eu and Ca contents by ICP-AES
(analyses preformed by the MARION TECHNOLOGIES Company,
Verniolle, France).
3. Results and discussion
3.1. Biomimetic apatite colloids in view of cancer-related medical
imaging
3.1.1. Physico-chemical aspects
The colloidal apatite-based suspensions prepared in this work,
in the presence of 2-aminoethylphosphate (AEP), correspond to an
experimental europium content of 2 at.% relative to calcium as indi-
cated by ICP-AEP evaluations. Also, the (Ca + Eu)/P and AEP/apatite
molar ratios were found to be close to 1.60 and 0.63, respectively.
The possibility to substitute some Ca2+ ions by Eu3+ in the apatite
structure has indeed been already shown (e.g. Boyer et al., 2000).
XRD analysis carried out on a typical dialyzed and freeze-dried
colloid (Fig. 1a) confirmed the apatitic nature of the crystallized par-
ticles prepared, with no detectable traces of secondary phases. FTIR
spectral features (Fig. 1b) corroborated these findings. The presence
of AEP molecules associated with the apatite phase was indicated
by the presence of an absorption band at 754 cm−1,  linked to P–O(C)
libration in systems such as Ca(AEP)2 involving a close interaction
between AEP and Ca2+ ions, as was discussed in our previous works
(Bouladjine et al., 2009; Al-Kattan et al., 2010). Moreover, in these
studies the adsorption of the AEP molecules on the surface of apatite
nanoparticles was evidenced, explaining the colloidal stabilization
effect by way of electrostatic repulsions among adjacent particles
through the ammonium –NH3
+ terminal groups of the grafted AEP
molecules. The zeta potential of the colloids prepared in the present
work was found to be close to +12 ± 3 mV, and this positive value
is indeed in good agreement with this statement. Although this
zeta potential measure may appear rather low in absolute value,
a
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Fig.  1. (a)  XRD patterns  and (b) FTIR spectra  for  apatite  colloidal nanoparticles.
the colloidal stability could be assessed macroscopically (by opti-
cal observations) and the as-synthesized colloids did not undergo
sedimentation. However, it should be noted here that a  complete
follow-up of the stability over time of such colloidal suspensions
was out of the scope of the present study, and will be regarded in a
detailed upcoming work.
TEM observations of such colloids (Fig. 2a) pointed out the
homogeneous ellipsoidal morphology of the nanoparticles, with a
mean length of the order of 25 ± 3 nm and a mean width of 7 ± 1 nm
(as determined from image processing carried out with the ImageJ
software). DLS measurements (Fig. 2b) confirmed the nanometer-
scale dimensions of the particles, with a unimodal size distribution
centered around 30 nm.
The luminescence properties of the colloids were also investi-
gated (Fig. 3). Excitation spectra recorded by monitoring the red
luminescence intensity or Eu3+ at 612 nm (main emission line)
showed two main emission peaks upon excitation at 392.8 nm
(major peak) and 464.2 nm corresponding, respectively, to the
7F0→
5L6 and
7F0→
5D2 intraconfigurational transitions. These
low-energy excitation domains (as compared for example to sys-
tems excitable solely under UV wavelengths) thus enable one to
envision the investigation of biological material while preventing a
premature deterioration. Luminescence emission spectra recorded
under excitation at 392.8 nm indicated the presence of three main
domains in the ranges 575–580 nm, 583–603 nm, and 605–627 nm,
corresponding, respectively, to the transitions from the 5D0 excited
state to the 7F0,
7F1 and
7F2 states of Eu
3+.
The luminescence decay time  (defined as the time for which
I() = I0/exp(1)) of the europium
5D0 level was also measured,
reaching 0.74 ± 0.03 ms. This value of the order of a millisecond
is remarkably lager than the typical decay times for the auto-
fluorescence of biological tissues thus adding to the potential
Fig.  2. (a)  TEM  micrograph  and (b) DLS data for  apatite  colloidal nanoparticles.
interest of such luminescent nano-systems as biologically oriented
nanoprobes.
The above data stress that Eu-doped apatite colloids can be pre-
pared, in aqueous medium, and that they may be considered for
applications in the field of medical imaging, in particular due (i) to
the biocompatible nature of their constituents (biomimetic apatite
and phospholipid moiety), (ii) to the nanometer-scale dimensions
of the particles (typically ∼30 nm) aiming at facilitating internal-
ization by cells, (iii) to the possibility to excite these systems under
(low-energy) visible or close-to-visible light domains, and (iii) to
the long luminescence lifetime as compared to the autofluores-
cence of biological tissues.
An interesting aspect to address when nanoparticles–cells inter-
actions are envisioned concerns the possibility to target a specific
type of cells (or tissue) so as to develop “intelligent” diagnosis or
therapeutic tools. In this context, several potential targeting agents
can be envisaged depending on several parameters such as the
type of pathology, the nature of the targeted cells, the degree of
specificity of the targeting agent, etc.
Folic acid (vitamin B9 or “FA”) is an example of targeting agent
that has led to numerous studies worldwide in the field of oncology.
Indeed, various works have shown that certain types of cancer cells
(e.g. some ovarian or breast cancer cells for instance) were over-
expressing on their membrane some specific folate receptors FR
(e.g. Antony, 1992; Parker et al., 2005) which exhibit a high affinity
for the folic acid molecule (about 100 000 times greater than that of
the reduced folate receptors that are usually present on the surface
of normal cells, (Spinella et al., 1995)). Another interesting feature
is that folic-acid-mediated endocytosis was generally observed for
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Fig.  3. Luminescence  properties of  apatite  colloidal  nanoparticles:  excitation  and
emission  (with or without FA  functionalization)  spectral  features.
FA-functionalized nano-systems, right after recognition of FA by
the FR receptors (Kamen et al., 1988).
In the present work, we thus focused on the physico-chemical
feasibility of FA association on our apatite colloidal nanoparticles.
Taking into account the two carboxylate groups of the glutamic
acid-like head of the FA molecule, we thus suspected a favorable
adsorption of FA molecules on the surface of apatite nanocrystals
by way of Ca2+ accessible surface ions.
Our attempts to functionalize the surface of apatite colloidal
nanoparticles by introducing FA in the reacting mixture (either
before or after the aging step), at a typical concentration of
0.45 mmol/l, proved to be successful. Apart from a clear yellow
color for the colloids (due to the presence of FA) the main physico-
chemical characteristics of the nanoparticles were retained. In
particular, no secondary crystallized phase was detected from
XRD analyses which were similar to the FA-free samples, and
the 754 cm−1 IR absorption band assignable to the presence of
AEP molecules was conserved. The DLS- and TEM-derived mean
particle size (43 ± 5  nm) remained also essentially unchanged. C,
H, N elemental analyses on freeze-dried nanoparticles led to an
FA content of 1.03 mg/100 mg of dried suspension. This low con-
centration in FA did not allow us to detect its presence by FTIR
spectroscopy; however the use of greater FA concentrations (4–40
times greater) led to the appearance of absorption bands char-
acteristic of calcium folate in the region 940–1800 cm−1,  next
to the bands characteristic of the apatite phase, in particular at
1590 and 1396 cm−1 (not shown for the sake of brevity). On
the contrary, the typical bands of free folic acid (especially at
1671 cm−1)  were not seen. These data evidenced the existence
of FA–Ca2+ interactions and thus confirm the physical attach-
ment of FA molecules on the nanoparticles surface, as initially
planned.
Luminescence spectra on the FA-functionalized colloids were
then recorded as previously, after excitation at 392.8 nm (see Fig. 3).
As for the FA-free suspensions, the spectra were characteristic of
the Eu3+ emitting centers despite a  baseline drift due to the pres-
ence of the grafted FA molecules. The luminescence decay time was
also determined (FA = 0.74 ms) and was found to be unmodified by
the presence of FA.
3.1.2. Cytotoxicity assessments
For a concentration of nanoparticles in the culture medium
between 0 and 1 mg/ml, the tests carried out on AMSC cells (see
Fig. 4 for FA-functionalized colloids) indicated a cell viability close
to 100%, whatever the incubation time between 1 and 7 days. These
results were found to be independent on the presence or absence
of FA on the nanoparticles. For greater concentrations in nanopar-
ticles, the cell viability started to decline thus enabling to consider
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Fig. 4. MTT  cytotoxicity  data  for apatite-based  colloids  functionalized  by FA,  for  AMSC  and ZR-75-1  cells.
the 1 mg/ml value as the inflexion value for these colloids on AMSC
cells.
Similar tests were also carried out on ZR-75-1 cancer cells (that
do not overexpress folate receptors), and the data (Fig. 4) indicated
that the inflexion of the cytotoxicity curve occurred in the range
1–2 mg/ml.
These findings point out the low cytotoxicity of these colloidal
systems, at least for such cells which do not specifically respond to
folic acid. These findings will be taken as reference for future works
on these colloids. Additional experiments are in progress on cells
that overexpress folate receptors.
3.1.3. Investigation of pro-inflammatory potential
The pro-inflammatory potential of the apatite colloidal
nanoparticles prepared was investigated here by following their
interaction with Human monocytes, via the evaluation of the
amount of ROI produced by the cells (luminol-enhanced chemi-
luminescence).
Chemiluminescence measurements (Fig. 5), carried out after 1 h
of contact between the colloidal nanoparticles (purified by dialy-
sis and stabilized at physiological pH) and the monocytes, and for
concentrations in nanoparticles between 0 and 120 mg/ml showed
no significant effect (i.e. activator or inhibitor) on the production
Fig.  5. Luminol-enhanced  chemiluminescence  intensity  measurements for  mono-
cytes  contacted  with colloidal apatite  nanoparticles  (1 h contact  time).
Fig.  6. SEM  micrograph  of  LMAP  microspheres  loaded  with  erythrosin  (ERY-LMAP)  (initial  magnification  200×),  and  particle size distribution  according  to  laser  light scattering
measurements.
of ROI. These results indicate that the intrinsic pro-inflammatory
potential of such colloids is low and remains undetectable after 1 h
of contact.
3.1.4. Study of apatite colloidal nanoparticles internalization by
ZR-75-1 breast cancer cells
This study was aimed at examining, in a preliminary approach,
the possibilities of internalization of our colloidal nanoparticles by
cells. For these tests, ZR-75-1 breast cancer cells were used. The
concentration of nanoparticles in the culture medium was set to
1.5 mg/ml, with a contact time of 24 h at 37 ◦C. ICP-AES measure-
ments were then carried out after cell washing, counting, and acidic
treatment (see Section 2): the quantitative data obtained indi-
cated that the Ca and Eu contents in the acidic aliquots increased
after being contacted with the nanoparticles, leading to the ratio
between the increase in Eu (initially absent of the cytoplasm) and
the increase in Ca of Eu/Ca = 0.088 ± 0.002 mass ratio. This value
corresponds to a Eu/(Ca +  Eu) molar ratio of 0.022 ± 0.006, which is
in perfect agreement with the Eu/(Ca + Eu) molar ratio characteris-
tic of the initial nanoparticles (2%).
Such results can be explained by the existence of a close interac-
tion between the nanoparticles and the cells during the contacting
time, leading to an internalization of the particles. Taking into
account the small size of the particles (of the order of 30–40 nm),
cell internalization through the endocytosis process appears as the
most probable scenario, although this question will require further
examination.
These first results confirm the possibility to use such nano-
systems for biomedical applications requiring an intracellular
action (either in terms of diagnosis or of therapeutics). Additional
experiments are in progress with cells overexpressing folate recep-
tors, so as to potentially evidence an increased internalization rate
in the case of nanoparticles associated with folic acid.
Preliminary analyses by optical microscopy coupled with a
spectrophotometer, carried out on air-dried colloids, have pointed
out the europium signature of the particles by showing lumines-
cence peaks around 590 and 615 nm (upon excitation at 365 nm).
Additional experiments are now planned for investigating the
possibility to detect the europium luminescence signature for cell-
internalized particles.
3.2. Biomimetic apatite–pectin microspheres composites
In the following sections, we address the elaboration of new
biomimetic apatite-based composite biomaterials involving LMAP
microspheres as drug reservoirs distributed within the biomimetic
apatite matrix.
3.2.1. Physico-chemical aspects
Generally speaking, the association of a drug with mineral bone
repair scaffolds is not a  straightforward task, in particular due
to the relative fragility of the organic molecules (usually heat-
sensitive) constituting the drug. The processing of scaffolds for
bone engineering often requires heat treatments/sintering at high
temperature. In these cases however, the drug/scaffold association
can then only be considered as a subsequent step, after cooling,
for example by filling (generally imperfectly) the accessible open
porosity of the scaffold by immersion in a  solution containing the
drug, followed by drying steps. A better suited way for perform-
ing drug/scaffold associations can nonetheless be considered if
the scaffold characteristics allow its preparation and processing
without the use of elevated temperatures and/or the appliance of
large mechanical pressures. In this view, along with their intrinsic
biomimetism properties, nanocrystalline apatites then represent
an interesting class of material due to the possibility to obtain
robust biomaterials at low or ambient temperatures (Grossin et al.,
2010) even without pressing procedures. As stated earlier, the pos-
sibility to associate a calcium phosphate cement (CPC) with drugs
has been reported (Ruhe et al., 2005; Habraken et al., 2008; Girod-
Fullana et al., 2010). However, the kinetics of cement hardening,
inducing a hydrolysis reaction, as well as the apatite characteris-
tics (apatite being the final state of hardened CPC) are generally
modified by the amount and nature of additives in the system.
Also, pH variations and exothermic effects often accompany the
cement hardening process, which may also potentially alter some
drugs.
In this study, we thus investigated the possibility to associate
LMAP microspheres with a biomimetic apatite phase obtained by
direct precipitation as a gel, without any heating or high pressure
treatment in the processing route.
Pectin is a naturally occurring heterogeneous water-soluble
polysaccharide which is found in the cell wall of most plants.
It consists mainly of linearly connected a-(1,4)-d-galacturonic
acid monosaccharide units that may be methyl-esterified or
amidated to varying extents. Low methoxy (with a  degree of
esterification DE < 50%) pectins (LMPs) and LM amidated pectins
(LMAPs) can gel with an “egg box” configuration in the pres-
ence of many divalent cations (Grant et al., 1973), allowing the
formation of microspheres by ionotropic gelation, without any
use of organic solvents and harsh ingredients. Pectin is bio-
compatible, biodegradable (Orhan et al., 2006) and has recently
demonstrated its potential interest to be used in the surface mod-
ification of medical devices and materials (Morra et al., 2004;
Ichibouji et al., 2008) and particularly bone implant nanocrys-
talline coatings (Kokkonen et al., 2007, 2008, 2010; Bussy et al.,
2008).
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Fig.  7. Swelling  properties  of LMA-pectin  microspheres  loaded  with  erythrosine in
SBF  pH  7.25.
A LMAP with a  DE of 30 and a degree of amidation (DA) of
19 was chosen, as we found it suitable for the elaboration of
organic–mineral composites (Girod-Fullana et al., 2010).
As a first step, LMAP microspheres loaded with erythrosin B
(ERY-LMAP) were prepared by ionotropic gelation in the pres-
ence of calcium ions. LMAP microspheres loaded with erythrosin B
(ERY-LMAP) were obtained instantaneously when LMAP solutions
were dropped into calcium bath. Intermolecular cross-links were
formed between the negatively charged carboxyl groups of LMAP
and the positively charged counter-ions, as previously described by
Grant et al. (1973) in  the “egg-box model”. After drying, the result-
ing microspheres were characterized in terms of size distribution
and morphology. Loaded LMAP microspheres with a weight aver-
age of volume distribution D[4;3] of 195 mm were obtained, with
monomodal and narrow particle size distribution (polydispersity
index of 0.64) (Fig. 6). Microspheres appeared spherical to ovoid
with a smooth surface when observed by SEM.
The swelling property of ERY-LMAP microspheres was then
studied (Fig. 7). The weight gain raised sharply within the first
40 min until it reached a plateau. No downward trend in the curve,
sign of microspheres erosion or degradation could be observed
during the experiments. Once dried microspheres placed in aque-
ous media, high calcium chloride concentration entrapped in the
microspheres exerted an osmosis phenomenon and water was
absorbed, inducing swelling of the microspheres. Microspheres fur-
ther stability can be explained by the strength of their network
structure, due to the formation of stable interchain junction zones
between each calcium ion and two carboxyl groups, reinforced by
the presence of calcium ions in SBF.
Composite apatite–LMAP disks were obtained as detailed in
Section 2. Gel drying carried out at 4 ◦C led, in our experimen-
tal conditions, to an amorphous compound as indicated by FTIR
and XRD analyses (not shown). In contrast, an apatite phase was
obtained upon drying at either 20, 37 or 50 ◦C as shown by XRD
and FTIR analyses which pointed out apatite as the only crystallized
phase in the system (Fig. 8). However, the dried composite disks
obtained at 37 or 50 ◦C exhibited apparent flaws such as fracture
lines (cracks) and these drying conditions were thus considered
as inappropriate. These findings may probably be linked in these
cases to a high drying rate, involving strong mechanical strains over
short periods of time. In contrast, the composite disks obtained at
RT (∼20 ◦C) revealed an undamaged aspect and this drying tem-
perature was then used for subsequent experiments. The volume
decrease accompanying the drying step at RT was found to be of
the order of 50%.
Fig.  8. (a) XRD patterns  and  (b) FTIR  spectra  for  apatite–LMAP  composites  (3% and
18%  LMAP)  and for  ceramic  alone.
The presence of LMAP microspheres (introduced in varying
amounts) dispersed within the apatite matrix was evidenced
by optical microscopy imaging. Additionally, XRD and FTIR data
showed that the physico-chemical characteristics of the apatite
phase remained basically unchanged independently of the amount
of LMAP microspheres associated to the mineral phase. Also, chem-
ical analyses indicated that the Ca/P ratio of the apatite phase was
essentially constant and close to 1.53 ± 0.04 (characteristic of non-
stoichiometric biomimetic-like apatites) for LMAP w/w contents
between 0% and 18% (corresponding to a mass of LMAP between
0 and 300 mg). These findings are particularly interesting as they
show, contrarily to the cement processing route, that a single pro-
tocol can be set up for preparing various apatite–LMAP composites,
where the amount of LMAP microspheres can be tailored as a func-
tion of the desired dose, regardless of the characteristics of the
apatite phase that will remain unchanged. The upper limit of micro-
spheres incorporation ratio into apatite is the consequence of their
swelling properties and could be modulated by an accurate choice
of pectin amidation and methoxylation degree. It was found to be
about 10% (w/w) in the case of a pectin with a DA of 19% and DE of
30%.
It was thus interesting at this point to study the possibility to
use these systems for a local drug delivery after implantation. In
this view, using erythrosine as  a model molecule, we investigated
the release properties of the apatite matrix alone and of typical
composite disks containing 6 and 9% (w/w) LMAP.
3.2.2. Release properties of apatite–LMAP microspheres
composites
Composites in vitro drug release properties were evaluated for
1 week in SBF pH 7.25 at 37 ◦C, in order to mimic the ionic condi-
tions encountered when implanted in vivo (Kokubo and Takadama,
2006). Erythrosin B was chosen as model drug because it is an
anionic dye, fluorescein analog, presenting higher solubility at basic
pH (it is a weak acid with a pKa of 5.04), allowing us to study the
release of a drug able to diffuse freely out of the composites without
Table  1
Kinetic  analysis  of  erythrosin release  from apatite–LMAP  microspheres  composites;  comparison  with LMAP  microspheres  and apatite  reference.
Cumulated  erythrosin
released within  the first
24  h  (%)
Cumulated  erythrosin
released after  7  days  (%)
Higuchi  model  coefficient
of determination r2
Higuchi  dissolution
constant  kH (%  h−1/2)
Apatite/ERY-LMAP  6%  6.43 ± 0.92  17.23  ± 0.67  0.994  1.358
Apatite/ERY-LMAP  9% 7.88 ± 0.74  20.13  ± 0.76  0.997  1.563
ERY-apatite  97.36  ± 2.63  100.06  ± 0.64  0.992  33.153
ERY-LMAP  microspheres  50.04 ± 2.61  78.1  ± 0.98  0.923  9.711
presenting specific interactions with the apatite phase or LMAP. In
our operating conditions, an encapsulation efficiency of 68% and
a drug loading of 15% of erythrosin B  into LMAP microspheres
were obtained. Reaching better entrapment efficiency was not the
purpose of our study, but it could be optimized by playing with
the counter-ion type and concentration, with the pH of the cross-
linking bathes and with the composition of the rinsing solutions
before drying (Chambin et al., 2006). Dry ERY-LMAP microspheres
were incorporated into the apatite matrix at weight ratios of 6% and
9%, leading to composites with an increasing drug loading. Release
patterns were presented by plotting the cumulated percentage of
erythrosin B released versus time.
Fig. 9 displays the release profiles of erythrosin B according to
LMAP microspheres ratio into the composites. They were almost
identical in shape, presenting a very limited initial burst in the ini-
tial 24 h (see Table 1) followed by a slow and sustained drug release.
The release data were simulated using Higuchi theory which inves-
tigated whether the erythrosin B cumulative release percentages
from composites were proportional to the square root of time. They
correlated well with this model, suggesting that erythrosin B was
released by Fickian diffusion from all the composites during the
experiments.
Releases of similar levels of erythrosin B release from a pure
apatite compound (so-called “ceramic”) and from LMAP micro-
spheres were compared under the same experimental conditions
(Fig. 9). While the pure apatite sample released 100% erythrosin B
within 24 h, clearly showing that there is no interaction between
the apatite phase and the dye, the composite and microspheres
release patterns were sustained, demonstrating the role of LMAP
microspheres in controlling drug diffusion (Table 1). Such sustained
release can be explained by LMAP microspheres sensitivity to ionic
conditions. They behave as hydrophilic matrices whose release
ability is currently related to their swelling ability in dissolution
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Fig. 9. Erythrosin  in vitro release  from  apatite–LMAP  microspheres  composites  in
SBF  pH 7.25  at  37 ◦C  (×: apatite/ERY-LMAP  6%  composite;  :  apatite/ERY-LMAP9%
composite;  d: ERY-LMAP  microspheres;  N: ERY-apatite).
media (Chambin et al., 2006). The presence of calcium in the LMAP
surrounding has been shown to enhance cross-linking and aggre-
gation of the pectin chains (Sriamornsak, 1999). In our case, LMAP
microspheres are immersed in SBF medium, which contain cal-
cium ions, and surrounded by apatite in the case of composites,
thus swelling patterns and subsequently drug release were lim-
ited for microspheres and composites, in a greater extent for the
latter. Steric constraints might also have hindered microspheres
swelling within the composites. Additional drug diffusion through
Fig.  10. Fluorescence  confocal  microscopy  photographs  of cross  sections of  LMA-pectin microspheres  loaded  with erythrosine,  retrieved  from  the surface  of the composites
(a)  before  release  experiments  (D0);  (b) after  7  days of immersion  in  SBF  pH  7.25  at  37 ◦C  (D7).
the apatite porosity, some of them being partially blocked by LMAP
microspheres, could also explain this slowing down, whereas no
differences could be observed between the two LMAP ratios tested
during our experiments.
Although these results have to be completed by longer release
studies, they yet clearly show the interest of combining nanocrys-
talline apatite with LMAP microspheres to generate tailored drug
delivery systems with improved drug release properties.
After 1 week of release, LMAP microspheres were still intact and
could be retrieved from the bioceramic and observed by confocal
laser microscopy. Confocal fluorescence observation (Fig. 10) con-
firmed incorporated microspheres integrity and moderate swelling
after a week of immersion in SBF. Erythrosin B  distribution within
the microspheres and progressive diminution over time were
observable, even more clearly on microspheres located near the
periphery of the composites. A homogenous distribution of the
dye within the microspheres at day 0 (D0, Fig. 10a) and a  fluores-
cence diminution from the center to the outer of the particles at D7
confirmed a diffusion release mechanism.
These results are promising and illustrate the potential interest
of nanocrystalline ceramics in elaborating innovative drug release
systems that could find application in bone cancer therapy.
4. Conclusions
The data reported in this contribution enabled us to propose
and test novel approaches for the preparation, storage and process-
ing of biomimetic-apatite-based nanosystems produced in view of
cancer-related applications.
We showed first that hybrid luminescent colloidal nanoparticles
based on the association of Eu-doped biomimetic apatite nanocrys-
tals, a phospho-lipid moiety (AEP) and also possibly vitamin B9
(folic acid, a potential cell-targeting agent) exhibited a low cyto-
toxicity and pro-inflammatory potential and could be internalized
by ZR-75-1 breast cancer cells. These findings then allow one to
envision potential applications in intracellular imaging by lumi-
nescence, which will be addressed in future works.
In a second type of approach, the incorporation of LMA
pectin microspheres within a nanocrystalline apatite matrix led
to organic–mineral composites with original properties. Interest-
ingly, the presence and amount of pectin microspheres did not
modify the physico-chemical characteristics of the apatite phase.
In terms of drug delivery, sustained release of our model molecule
was obtained, whereas it developed no specific interaction with
apatite nor pectin. The presence of LMAP appeared as a  parameter
contributing to regulate drug diffusion. By adjusting their pectin
microspheres content, it should be possible to design tailorable
composites whose release rates could be controlled upon demand.
To our knowledge no previous studies concerning nanocrystalline
apatite-polymer microspheres composite materials had been pub-
lished previously.
These results add to the existing literature on synthetic
biomimetic nano-systems, by exploring these novel options in the
field of cancer diagnosis and treatment.
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